Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Celator Pharmaceuticals, the Leukemia & Lymphoma Society Announce Positive Data from Phase IIb Study of CPX-351
Dec. 13, 2011
Celator Pharmaceuticals announced positive clinical data in first relapse patients with acute myeloid leukemia treated with CPX-351 (cytarabine:Daunorubicin) Liposome Injection.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing